Study on the efficacy of compound porcine cerebroside and ganglioside injection in patients with ischemic stroke: A randomized, single-center, open-label, prospective study

Abstract

Compound porcine perebroside and ganglioside injection (CPCGI) was used to treat stroke. The study was initiated because of the high incidence of low-does CPCGI use in our area. However, no research has confirmed the effectiveness of CPCGI below the standard dose. Therefore, the aim of this study was to provide a reference for the clinical selection of different dose treatments. We collected ischemic stroke patients and divided them into three groups (low-dose group: Group A = 4 mL, Group B = 6 mL, standard-dose group: Group C = 10 mL). The modified Rankin Scale (mRS) scores, the National Institutes of Health Stroke Scale (NIHSS) scores, and the Barthel Index (BI) scores were performed before treatment and 14 days and 90 days post CPCGI treatment. For 90 days, the primary outcomes were calculated including the degree of disability, neurological recovery, and activities of daily living. All data were compared between pretherapy and posttreatment and among groups. NIHSS, mRS and BI scores improved on 14 and 90 days in each group. Group B and C improved than Group A on 14 and 90 days. The difference between groups B and C was not statistically significant. On 90 days, there were differences in the degree of disability, the recovery of neurological function, and the ability of daily living among groups. No drug-related adverse reactions occurred in the groups. Although 4 or 6 mL CPCGI had some neuroprotective effects, the standard dose of 10 mL CPCGI had the best effect on reducing the degree of disability and improving abilities of daily living.

Keywords

compound porcine cerebroside and ganglioside injection (CPCGI) / ischemic stroke / Modified Rankin Scale (mRS) / National Institutes of Health Stroke Scale (NIHSS) / neuroprotectant

References

[1] Zhang H, Li CL, Wan F, et al. Efficacy of cattle encephalon glycoside and ignotin in patients with acute cerebral infarction: a randomized, double-blind, parallel-group, placebo-controlled study. Neural Regen Res. 2020; 15(7): 1266-1273.

[2] Wu H, Gong W, Tang Y, Xu W, Zhou Y, Liu X. Meta-analysis of the effectiveness and safety of intravenous thrombolysis in patients with acute cerebral infarction. Comput Math Methods Med. 2021; 7: 2-11.

[3] Markus HS, Michel P. Treatment of posterior circulation stroke: acute management and secondary prevention. Int J Strock. 2022; 17(7): 723-732.

[4] Paul S, Candelario-Jalil E. Emerging neuroprotective strategies for the treatment of ischemic stroke: an overview of clinical and preclinical studies. Exp Neurol. 2021; 335: 113518-113538.

[5] Zhong J, Li RW, Wang J, et al. Neuroprotection by cattle encephalon glycoside and ignotin beyond the time window of thrombolysis in ischemic stroke. Neural Regen Res. 2021; 16(2): 312-318.

[6] Wang X, Zhao J. Neuroprotective effect of CPCGI on Alzheimer's disease and its mechanism. Mol Med Rep. 2019; 21(1): 115-122.

[7] Niu F, Qian K, Qi H, et al. CPCGI reduces gray and white matter injury by upregulating Nrf2 signaling and suppressing calpain overactivation in a rat model of controlled cortical impact. Neuropsychiatr Dis Treat. 2020; 16: 1929-1941.

[8] Miao Y, Wang R, Wu H, Yang S, Qiu Y. CPCGI confers neuroprotection by enhancing blood circulation and neurological function in cerebral ischemia/reperfusion rats. Mol Med Rep. 2019; 20(3): 2365-2372.

[9] Park HS, Han KH, Shin JA, Park JH, Song KY, Kim DH. The neuroprotective effects of carnosine in early stage of focal ischemia rodent model. J Korean Neurosurg Soc. 2014; 55(3): 125-130.

[10] Zamfir AD. Neurological analyses: focus on gangliosides and mass spectrometry. Adv Exp Med Biol. 2014; 806: 153-204.

[11] Inamori K, Inokuchi J. Ganglioside GM3 synthase deficiency in mouse models and human patients. Int J Mol Sci. 2022; 23(10): 5368-5380.

[12] Sandhoff R, Sandhoff K. Neuronal ganglioside and glycosphingolipid (GSL) metabolism and disease: cascades of secondary metabolic errors can generate complex pathologies (in LSDs). Adv Neurobiol. 2023; 29: 333-390.

[13] Wang M, Zhang Y, Feng L, et al. Compound porcine cerebroside and ganglioside injection attenuates cerebral Ischemia-reperfusion injury in rats by targeting multiple cellular processes. Neuropsychiatr Dis Treat. 2017; 13(7): 927-935.

[14] Niu F, Qian K, Qi H, Zhao Y, Jiang Y, Sun M. Antiapoptotic and anti-inflammatory effects of CPCGI in rats with traumatic brain injury. Neuropsychiatr Dis Treat. 2020; 16: 2975-2987.

[15] Zhang XJ, Duan HZ, Hua W, Xiao SW, Yang SL, Yu AY. Clinical trial of compound cerebropeptide and ganglioside in the treatment of acute brain injury and on the effect of serum neuron regeneration factor. Chin J Clin Pharmacol. 2020; 36(5): 493-502.

[16] Xingming L, Liu JJ, Chen JB, Liu JX, Jiao CZ. Clinical effect of compound cerebral peptide glycoside injection on acute cerebral infarction and the effect on LP-PLA2 hs-CRP and NSE levels in patients[J]. Hebei Med. 2020; 26(3): 297-397.

[17] Reeves MJ, Hughes AK, Woodward AT, et al. Improving transitions in acute stroke patients discharged to home: the Michigan stroke transitions trial (MISTT) protocol. BMC Neurol. 2017; 17(1): 115.

[18] Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018; 49(3): 46-110.

[19] Bin Peng, Bo Wu. Chinese guidelines for the diagnosis and treatment of acute ischemic stroke. Zhonghua Shenjing Zazhi. 2018; 51(9): 666-682.

[20] Uyttenboogaart M, Stewart RE, Vroomen PCAJ, De Keyser J, Luijckx GJ. Optimizing cutoff scores for the Barthel index and the modified Rankin scale fordefining outcome in acute. Stroke. 2005; 36: 1984-1987.

[21] Meyer BC, Hemmen TM, Jackson CM, Lyden PD. Modified National Institutes of Health stroke scale for use in stroke clinical trials: prospective reliability and validity. Stroke. 2002; 33(5): 1261-1266.

[22] Choi JC, Kim BJ, Han MK, et al. Utility of items of baseline national institutes of health stroke scale as predictors of functional outcomes at three months after mild ischemic stroke. J Stroke Cerebrovasc Dis. 2017; 26(6): 1306-1313.

[23] Quinn TJ, Langhorne P, Stott DJ. Barthel index for stroke trials: development, properties, and application. Stroke. 2011; 42(4): 1146-1151.

[24] Basagni B, Hakiki B, Campagnini S, et al. Critical issue on the extinction and inattention subtest of NIHSS scale: an analysis on post-acute stroke patients attending inpatient rehabilitation. BMC Neurol. 2021; 21(1): 475-478.

[25] yuxian Y, Ming F. Effect analysis of compound brain peptide ganglioside in patients with acute intracerebral hemorrhage. Zhongxiyi Jiehe Xinxueguan Zazhi. 2016; 4(3): 28-32.

[26] Zhongming G, Xiaoming S, liming W, Li Y. Clinical effect of compound cerebral peptidoside injection on cognitive impairment after cerebral infarction. China Prac Med. 2018; 13(10): 105-106.

[27] Zhanjian D, Naiqing Z, Suiheng L. A method to allocate sample size into each region in multiregional clinical trial. Fudan Univ J Med Sci. 2009; 36(2): 231-234.

[28] Britton M, Carlsson A. Very high blood pressure in acute stroke. J Intern Med. 1990; 228(6): 611-616.

[29] Zhu Y, Wu M, Wang H, et al. Daily blood pressure variability in relation to neurological functional outcomes after acute ischemic stroke. Front Neurol. 2023; 13: 958166-958178.

[30] van den Berg SA, Uniken Venema SM, Mulder MJHL, et al. Admission blood pressure in relation to clinical outcomes and successful reperfusion after endovascular stroke treatment. Stroke. 2020; 51(11): 3205-3214.

RIGHTS & PERMISSIONS

2023 The Authors. Ibrain published by Affiliated Hospital of Zunyi Medical University (AHZMU) and Wiley-VCH GmbH.